The first chlamydia vaccine to reach Phase I clinical trials has been observed to be safe and immunogenic in 35 women.
The manipulation of public opinion against lifesaving medicine and scientific facts is becoming an increasingly dangerous problem, but what can the science community do to convince people of the truth?
Respiratory syncytial virus: experimental structure-based vaccine candidate shows promise in Phase I trial
Researchers from the University of Texas at Austin have passed an experimental RSV vaccine through Phase I human clinical trial with promising results.
US FDA approves RECARBRIO™ for complicated UTIs and complicated intra-abdominal infections: July’s industry headlines
Take a look at this month’s industry headlines including a US FDA approval for RECARBRIO™, positive results for XOFLUZA in children and new ACIP recommendations.
A DNA vaccine for MERS-CoV was demonstrated to be well-tolerated and immunogenic in a Phase I, first-in-human trial.
New research has revealed a dangerous stagnation in the global vaccination rates of children, owing to inequality, conflict and complacency.
Take a look at this month’s industry headlines including an FDA approval for Zebraxa, new…
A new meta-analysis including data from 60 million individuals over 8 years has demonstrated significant decreases in HPV infections, anogenital wart diagnoses and precancerous cervical lesions following HPV vaccination in girls.
New study determines a neutralizing antibody which binds to the most pandemic strain of norovirus in humans that could be utilized for an effective vaccine.
A study has revealed genetic variants associated with differing levels of protective antibodies produced after routine immunizations.